Beleave Inc. Stock

BLEVF

CA0775611084

Pharmaceuticals

Market Closed - OTC Markets 15:06:48 2026-10-20 EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	-

20-06-16	Beleave Inc. Appoints Bill Panagiotakapoulos as Chief Restructuring Officer	CI
20-06-04	Hegedus Consulting Services Inc. agreed to acquire Substantially All of the Assets from Beleave Inc. (CNSX:BE).	CI

Beleave Inc. is a Canada-based cannabis company. Through its wholly owned subsidiary, Beleave Kannabis Corp, the Company is a license holder and producer of cannabis, which includes cultivation, processing, medical sales and research. Its segment includes Cannabis Products and Patient Network. Its Cannabis Products segment is a licensed producer of marihuana for medical purposes. Its Patient Network segment is a patient network of medical cannabis services. It cultivates cannabis flower, oil and extracts for medical and recreational markets. Its product line includes cannabis-infused products, oils and vape pens. The Company operates a network of medical cannabis clinics in Ontario and Quebec under the Medi-Green banner.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-10-20	US$0.000001	0.00%	2,415

Delayed Quote OTC Markets

More quotes

Stock Market
Stocks
BLEVF Stock

As early as today, start finding the best investment opportunities!

Market Cap	7.65M 6.83M 6.3M 5.72M 10.73M 724M 10.9M 75.87M 29.89M 380M 28.71M 28.09M 1.2B	P/E 2018	-4.72x	P/E 2019	-0.76x
Enterprise Value	17.96M 16.03M 14.79M 13.44M 25.21M 1.7B 25.6M 178M 70.2M 891M 67.43M 65.98M 2.82B	EV / Sales 2018	-	EV / Sales 2019	17,137,012x
Free-Float	98.39%	Yield 2018 *	-	Yield 2019	-

20-06-16	Beleave Inc. Appoints Bill Panagiotakapoulos as Chief Restructuring Officer	CI
20-06-04	Hegedus Consulting Services Inc. agreed to acquire Substantially All of the Assets from Beleave Inc. (CNSX:BE).	CI
20-04-13	Beleave Inc. Announces Management Changes	CI
20-03-02	Beleave Inc. announced that it expects to receive CAD 0.5 million in funding	CI
20-03-02	Beleave Inc. Enters LoI with Dutchman's Gold to Partner on Cannabis Infused Honey Products	CI
20-03-02	Beleave Inc. Approves for Sales in the Province of Alberta	CI
20-02-26	Beleave Expands Cannabis 2.0 Product Roll Out to British Columbia with Flyte Classic Vaporizer	CI
20-02-25	Beleave Inc. announced that it has received CAD 0.27 million in funding	CI
19-12-19	Beleave Inc. Announces New Product Line; Receives the Largest Purchase Order from A Province in the Company's History	CI
19-12-19	Beleave Inc. Announces Management Changes	CI
19-10-31	Beleave Announces Joint Venture with Volero Brands to Launch Cannabis 2.0 Products in Canada	CI
19-10-28	Beleave Inc. Announces Management Appointments	CI
19-09-18	Beleave Inc. (CNSX:BE) cancelled its acquisition of TerraFarma, Inc.	CI

20-04-29	Beleave Refiles Amended and Restated MD&A and Financial Statements	NE
20-04-20	Beleave Files Amended and Restated Financial Statements	NE
20-04-17	Beleave's Q3 Financials Should Not Be Relied Upon	NE
20-04-13	Beleave Provides Operational and Leadership Updates	NE
20-03-03	Beleave Enters LOI with Dutchman's Gold to Partner on Cannabis Infused Honey Products	NE

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0
3 years	0		0
5 years	0		0
10 years	0		0.4

Date	Insider	Type	Main position	Quantity	% Market Cap.
4/28/20	Jeannette VanderMarel	Tax	Chief Executive Officer	2,343,750	0.4350%
4/28/20	Andrew Steane	Tax	Director	2,343,750	0.4350%
4/28/20	Kevin Keagan	Tax	Chief Executive Officer	11,718,750	2.1751%

Beleave Inc. Stock

Stocks

BLEVF

CA0775611084

Pharmaceuticals

Valuation: Beleave Inc.

Chart: Beleave Inc.

Latest news: Beleave Inc.

Press Releases: Beleave Inc.

Price Extremes

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BELEAVE INC.	0.00%	0.00%	-	-	553
ELI LILLY AND COMPANY	+2.83%	+4.40%	+60.84%	+126.60%	1,133B
JOHNSON & JOHNSON	+3.81%	+5.66%	+38.70%	+76.77%	621B
ABBVIE INC.	+0.14%	+0.63%	+24.71%	+97.05%	503B
ROCHE HOLDING AG	+0.03%	+5.72%	+39.64%	+64.06%	379B
MERCK & CO., INC.	-1.76%	+1.41%	+68.06%	+42.47%	370B
NOVARTIS AG	+1.58%	+5.07%	+23.26%	+51.98%	292B
ASTRAZENECA PLC	+2.90%	+5.53%	+4.06%	+24.45%	262B
AMGEN INC.	+2.04%	+3.05%	+51.12%	+63.80%	237B
GILEAD SCIENCES, INC.	+2.36%	-0.11%	+29.42%	+102.67%	190B
Average	+1.29%	+2.89%	+37.76%	+72.21%	398.8B
Weighted average by Cap.	+1.70%	+3.73%	+42.92%	+84.30%

	2018	2019
Net sales	-	2.37 2.12 1.96 1.78 3.33 224.89 3.38 23.55 9.28 117.82 8.91 8.72 373.25
Net income	-12.64M -11.28M -10.41M -9.46M -17.74M -1.2B -18.02M -125M -49.4M -627M -47.45M -46.44M -1.99B	-33.78M -30.16M -27.82M -25.28M -47.42M -3.2B -48.15M -335M -132M -1.68B -127M -124M -5.31B
Net Debt	-5.2M -4.64M -4.28M -3.89M -7.3M -493M -7.41M -51.59M -20.32M -258M -19.52M -19.1M -818M	10.32M 9.21M 8.49M 7.72M 14.48M 977M 14.7M 102M 40.31M 512M 38.72M 37.89M 1.62B